Kunyangwe nekuvhiyiwa, radiotherapy, chemotherapy, uye / kana gene-targeted therapy (senge cetuximab), makore mashanu ekupona kwekenza yemusoro nemutsipa yemuno inongova 46%. Kazhinji, kurapwa kwakanaka pakutanga, asi kukura kwegomarara kunogona kutungamirira mukuramba zvinodhaka.
Vatsvagiri vepaYunivhesiti yeColorado Cancer Center vakawana kuti maviri emajini ane hukama nekukura kwehuropi, asi kunyarara muhutano hwevanhu vakuru kunokonzeresa kuramba mumasampuni emamota. Jeni iEphB4 uye jena rinoperekedza iri ephrin-B2. Ose majini anosimuka mushure mekunge murwere atadza kurapwa, saka unogona kuvanangisa kuti uone kana zvichibudirira.
Kuti izvi zviitike, vakashandisa bundu matishu kubva kuvarwere vakadzokazve kukura mumakonzo. Mbeva dzakazopatsanurwa kuita mapoka ekurapa, mamwe acho akawana chemotherapy cisplatin, vamwe vakagamuchira anti-EGFR drug cetuximab, uye vamwe vakagamuchira kurapwa kwemwaranzi vari voga kana kuwedzera kune idzi marapiro. Wedzera yekuedza EphB4-ephrin-B2 inhibitor kurapwa kune yakaparadzana cohort yeboka rega rega.
Muboka recisplatin, kushandiswa kwebundu remishonga itsva inhibitor kwakanga kusiri pachena, asi kuwedzerwa kweEphB4-ephrin-B2 inhibitor kune EGFR inhibitor cetuximab kurapwa kwakaderedza zvakanyanya kukura kwebundu, uye paive nekuwedzera Kwakanaka kwehuwandu hwekupona. Vatsvagiri vanotenda kuti EGFR neEphB4-efrin-B2 inogona kushandiswa sedzimwe nzira.
EphB4-ephrin-B2 inhibitors parizvino vari kuongororwa mumakiriniki mune mamwe magomarara. Tsvagiridzo yedu inoratidza kuti inogona kushandiswa zvinobudirira mukubatana neEGFR inhibitors yekurapa kwegomarara remusoro nemutsipa. Predictor yeEphB4-ephrin-B2 inogona kubatanidzwa nevarwere vebundu vanoratidza huwandu hwemapuroteni aya.
